{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:50:41Z","timestamp":1777881041139,"version":"3.51.4"},"reference-count":58,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"the general program of Development Center for Medical Science & Technology, National Health Commission of the People\u2019s Republic of China","award":["Grant NO. WKZX2023CX210006"],"award-info":[{"award-number":["Grant NO. WKZX2023CX210006"]}]},{"name":"2021 Chongqing Young and Middle aged Medical High-end Talent Project"},{"name":"Chongqing Clinical Pharmacy Key Specialties Construction Project"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Sage Open Medicine"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Baclofen is a muscle relaxant that could carry the risk for neurological adverse events (nAEs). We aim to analyze the nAE profile of frequently used baclofen for its clinical application.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Our research is a disproportional analysis based on the FDA Adverse Event Reporting System (FAERS) database. We obtained adverse event reports of baclofen from January 2004 to June 2023 from the FAERS database. Reporting odds ratio (ROR) and Bayesian confidence propagation neural network (BCPNN) were performed to find nAE associated with baclofen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We extracted a total of 9305 nAE cases with baclofen as the primary suspect. The patients were mostly under 18\u2009years old (45.49%), with markedly more males (43.72%) than females (36.52%). In all, 7275 (78.18%) reports were from the United States. There were 2023 of 9305 (21.74%) reports that occurred serious adverse events (SAE). The median onset time of reports with baclofen-related nAE was 10\u2009days (interquartile range (IQR) 1\u2013112). Intrathecal injection (75.78%) was more than oral (23.06%). We detected 119 significant signals, among which the higher frequencies were somnolence (ROR: 4.69, 95% CI (4.37, 5.03); IC: 2.17, IC025 (2.06)), tremor (ROR: 2.76, 95% CI (2.50, 3.04); IC: 1.43, IC025 (1.29)), lethargy (ROR: 6.37, 95% CI (5.71, 7.10); IC: 2.61, IC025 (2.45)), status epilepticus (ROR: 8.71, 95% CI (7.07, 10.73); IC: 2.98, IC025 (2.69)), generalized tonic-clonic seizure (ROR: 3.17, 95% CI (2.54,3.95); IC: 1.62, IC025 (1.30)], and cerebrospinal fluid leakage (ROR: 229.56, 95% CI (197.76, 266.47); IC: 6.61, IC025 (6.43)]. Unexpected significant nAE might also occur, such as intracranial hypotension (ROR: 428.52, 95% CI (355.18, 517.00); IC: 6.75, IC025 (6.56)], cognitive disorder (ROR: 2.65, 95% CI (2.21, 3.19); IC: 1.38, IC025 (1.11)], anterograde amnesia (ROR: 7.35, 95% CI (2.74, 19.72); IC: 1.69, IC025 (0.90)], metabolic encephalopathy (ROR: 14.77, 95% CI (10.40, 21.00); IC: 3.55, IC025 (2.93)], and myoclonus (ROR: 5.98, 95% CI (4.70, 7.59); IC: 2.46, IC025 (2.13)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Given the wide use of baclofen, clinicians should be well-informed about important potential nAE. Although disproportional analysis is a refinement approach, it is still necessary to be vigilant about the nAE of baclofen. It is extremely crucial to early monitoring, especially in minors and the initial stage following the commencement of use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20503121251331812","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T06:43:06Z","timestamp":1745822586000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Neurological adverse events associated with baclofen: A disproportionality analysis based on FDA Adverse Event Reporting System"],"prefix":"10.1177","volume":"13","author":[{"given":"Ni","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6277-3687","authenticated-orcid":false,"given":"Pei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical and Pharmaceutical College, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7507-2410","authenticated-orcid":false,"given":"Yao","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Daping Hospital of Army Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.0c00254"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006565-200104000-00008"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-012-1780-y"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2002.tb00267.x"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nefro.2020.03.004"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2008.05.002"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2023.03.011"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2022.11.004"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.17725"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.04.047"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15494"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","unstructured":"Zhang X Zhang Y Ye X et al. Overview of phase IV clinical trials for postmarket drug safety surveillance: a status report from the ClinicalTrials.gov registry. BMJ Open 2016; 6(11): e010643.","DOI":"10.1136\/bmjopen-2015-010643"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80007-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbab347"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/clt2.12038"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-199920020-00002"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.668"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050466"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010098"},{"key":"e_1_3_4_22_2","unstructured":"Administration USFD. What is a serious adverse event? https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event FDA (accessed 01-14)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15010027"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/15563650.2019.1687902"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231193080"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2020.01.044"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2020024"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12277"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31829b61ba"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(83)80562-9"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.101.6.1045"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2020.110541"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00448"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420986231200746"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-010-9422-6"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.psy.46.6.503"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.5811\/westjem.2011.2.11460"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2021.06.007"},{"key":"e_1_3_4_39_2","article-title":"Traditional pharmacological treatments for spasticity. Part II: General and regional treatments","volume":"6","author":"Gracies JM","year":"1997","unstructured":"Gracies JM, Nance P, Elovic E, et al. Traditional pharmacological treatments for spasticity. Part II: General and regional treatments. Muscle Nerve Suppl 1997; 6: S92\u2013S120.","journal-title":"Muscle Nerve Suppl"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211022197"},{"key":"e_1_3_4_41_2","first-page":"213","article-title":"Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders","volume":"97","author":"Richard I","year":"2007","unstructured":"Richard I, Menei P. Intrathecal baclofen in the treatment of spasticity, dystonia and vegetative disorders. Acta Neurochir Suppl 2007; 97(Pt 1): 213\u2013218.","journal-title":"Acta Neurochir Suppl"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.4103\/ijn.IJN_330_20"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/ner.12388"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNP.0000000000000565"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(91)90015-H"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-018-1167-z"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.89835"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)91697-7"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00404"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410360122"},{"issue":"3","key":"e_1_3_4_51_2","first-page":"348","article-title":"Self-induced drug intoxication in baclofen: of the calm hypotonic coma in the status epilepticus","volume":"74","author":"Thill C","year":"2016","unstructured":"Thill C, Di Constanzo L, Pessey F, et al. Self-induced drug intoxication in baclofen: of the calm hypotonic coma in the status epilepticus. Ann Biol Clin 2016; 74(3): 348\u2013352.","journal-title":"Ann Biol Clin"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(25)23488-7"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2022.12.039"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1159\/000112427"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0012162201001190"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1213\/ane.0b013e318165e1c6"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0869-z"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12400"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.3389\/fdsfr.2023.1323057"}],"container-title":["Sage Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251331812","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20503121251331812","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20503121251331812","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:30:20Z","timestamp":1777595420000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20503121251331812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":58,"alternative-id":["10.1177\/20503121251331812"],"URL":"https:\/\/doi.org\/10.1177\/20503121251331812","relation":{},"ISSN":["2050-3121","2050-3121"],"issn-type":[{"value":"2050-3121","type":"print"},{"value":"2050-3121","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"article-number":"20503121251331812"}}